FDA Decision July 24 on New ADHD Drug: What the Numbers Show

What the trials actually showed

Otsuka Pharmaceutical submitted a New Drug Application to the FDA for centanafadine in late 2025. The FDA accepted it for Priority Review, signaling it addresses an unmet medical need, with a Prescription Drug User Fee Act target decision date of July 24, 2026. The application covers children ages 6 and up, adolescents, and adults.

Three clinical trials supported the filing. A Phase 3 trial in 480 children ages 6 to 12 found high-dose centanafadine significantly outperformed placebo on the ADHD Rating Scale-5: 34% of children in the high-dose group achieved a clinically meaningful reduction (18 or more points) versus 23% in the placebo group. A separate Phase 3 trial in 459 adolescents ages 13 to 17 confirmed high-dose superiority over placebo and over the lower dose. Both trials ran six weeks. The most common side effects across age groups were decreased appetite, nausea, and fatigue, described as generally mild.

A Phase 3b trial in 315 adults with ADHD and comorbid anxiety disorder showed statistically significant improvement on the Adult Investigator Symptom Rating Scale (AISRS): centanafadine achieved a mean reduction of 18.5 points versus 12.6 for placebo (p < 0.0001). Anxiety symptoms also improved: centanafadine produced a Hamilton Anxiety Rating Scale reduction of 12.5 points versus 10.6 for placebo.

Centanafadine works differently from existing non-stimulants. It is a norepinephrine, dopamine, and serotonin reuptake inhibitor — a triple reuptake inhibitor — the first in that class proposed for ADHD. Atomoxetine (Strattera) targets only norepinephrine. Guanfacine and clonidine target a different receptor entirely. The addition of serotonin reuptake inhibition is what researchers believe accounts for the anxiety benefit seen in the Phase 3b trial.

Why the anxiety finding changes the picture for many families

Approximately half of children with ADHD have a co-occurring anxiety disorder. For those families, stimulant medications create a real dilemma. Amphetamines and methylphenidate increase dopamine and norepinephrine and raise arousal — which improves attention but frequently worsens anxiety in a child who is already anxious. The result is a parent forced to choose between two problems with no tool that addresses both. Centanafadine’s trial data suggests it addresses both simultaneously. That is a clinically meaningful difference for a predictable group of children who have been stuck in that either/or.

But the mainstream coverage of a new ADHD medication approval — “new drug, better treatment options” — routinely skips what the research on ADHD outcomes actually shows about what medication does and does not do. The NIMH Multimodal Treatment Study of ADHD, the largest ADHD intervention trial ever conducted (579 children, ages 7 to 9, 14 months of treatment), found that both medication-alone and combined treatment significantly reduced ADHD symptoms. But combined treatment — medication paired with intensive behavioral support — was the only group to show meaningful improvements in academic performance, parent-child relations, and social skills. Medication alone produced equivalent ADHD symptom scores without those broader gains. By the 36-month follow-up, the advantage of the medication group had largely faded; what remained was the benefit of skill-building.

Centanafadine is a non-stimulant. But the MTA finding holds for ADHD medication generally: a pill changes the symptom environment. It does not build executive function skills, it does not develop working memory or processing speed, and it does not do the work of teaching a child to manage their own attention. The framing that a prescription fills the gap leaves that part out. A new medication option is valuable. Treating it as the answer is where families get stuck.

What this means for your child this month

If July 24 passes and the FDA approves centanafadine, it will be good news for two specific groups: families who have tried stimulants and found them ineffective or intolerable, and families whose child has ADHD alongside anxiety and has been caught in the stimulant-worsens-anxiety bind. For those families, a new mechanism with clean Phase 3 data across ages is a real expansion of options worth discussing with a prescriber.

The questions worth asking go beyond what the clinical summary sheet covers. Beyond symptom scores on a rating scale, what does improvement look like in terms the school would see? Is a skill-building plan in place alongside any medication? Who is tracking executive function development, working memory, and reading fluency — not only behavior ratings from teachers? A child whose attention scores improve on a trial instrument while the underlying cognitive skills go unaddressed will still hit a ceiling. The medication changes the conditions; the building still has to happen.

If you suspect your child has ADHD-type attention challenges and you’re watching for what a potential new treatment option means, a screener is a useful starting point. A screener tells you where your child is today, in language that builds them up. It is not a diagnosis, and it is not a substitute for one — if your child might need formal school supports like an IEP or 504 plan, or you suspect a vision, hearing, or medical cause, a professional evaluation is the route to those supports. But the screener gives you organized, specific information before you walk into that evaluation room, and specific information is what gets children the right support faster.